



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Typhoid Fever - Pipeline Review, H1 2019

---

## Typhoid Fever - Pipeline Review, H1 2019

**Publication ID:**

GMD0119020

**Publication Date:**

January 31, 2019

**Pages:**

51

**Publisher:**

Global Markets Direct

**Region:**

Global [1]

**\$2,000.00**

Publication License Type \*

Single User License (PDF), \$2,000.00

Site License (PDF), \$4,000.00

Global License (PDF), \$6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



**Description:**

Typhoid Fever - Pipeline Review, H1 2019

## Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Pipeline Review, H1 2019, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.

Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called *Salmonella typhi* (*S. typhi*). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

## Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 1, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Unknown stages comprises 1, 1 and 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease)

#### Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

#### **Table Of Contents:**

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Typhoid Fever - Overview

Typhoid Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Typhoid Fever - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Typhoid Fever - Companies Involved in Therapeutics Development

Eubiologics Co Ltd

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Ology Bioservices Inc

Prokarium Ltd

Protein Potential LLC

Sanofi Pasteur SA

Shantha Biotechnics Pvt Ltd

Walvax Biotechnology Co Ltd

Typhoid Fever - Drug Profiles

(paratyphoid (bivalent) + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(paratyphoid + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(rotavirus (virus like particle) + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(shigella + typhoid) (Bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Streptococcal pneumonia + typhoid) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EUC-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Typhella - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vi-CRM197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ViCRM-197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Typhoid Fever - Dormant Projects

Typhoid Fever - Discontinued Products

Typhoid Fever - Product Development Milestones

Featured News & Press Releases

Oct 08, 2012: Typhim Vi - Typhoid Polysaccharide Vaccine - antigen levels below required specification

Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine

Jun 23, 2011: Sanofi Pasteur's Typhim Vi Receives Prequalification From World Health Organization

Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate

Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine

Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine

Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study

Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Typhoid Fever, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019  
Typhoid Fever - Pipeline by Eubionics Co Ltd, H1 2019  
Typhoid Fever - Pipeline by GlaxoSmithKline Plc, H1 2019  
Typhoid Fever - Pipeline by Indian Immunologicals Ltd, H1 2019  
Typhoid Fever - Pipeline by Ology Bioservices Inc, H1 2019  
Typhoid Fever - Pipeline by Prokarium Ltd, H1 2019  
Typhoid Fever - Pipeline by Protein Potential LLC, H1 2019  
Typhoid Fever - Pipeline by Sanofi Pasteur SA, H1 2019  
Typhoid Fever - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2019  
Typhoid Fever - Pipeline by Walvax Biotechnology Co Ltd, H1 2019  
Typhoid Fever - Dormant Projects, H1 2019  
Typhoid Fever - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Typhoid Fever, H1 2019  
Number of Products under Development by Companies, H1 2019  
Number of Products under Development by Universities/Institutes, H1 2019  
Number of Products by Targets, H1 2019  
Number of Products by Stage and Targets, H1 2019  
Number of Products by Routes of Administration, H1 2019  
Number of Products by Stage and Routes of Administration, H1 2019  
Number of Products by Molecule Types, H1 2019  
Number of Products by Stage and Molecule Types, H1 2019

#### **Companies Mentioned:**

Eubionics Co Ltd  
GlaxoSmithKline Plc  
Indian Immunologicals Ltd  
Ology Bioservices Inc  
Prokarium Ltd  
Protein Potential LLC  
Sanofi Pasteur SA  
Shantha Biotechnics Pvt Ltd  
Walvax Biotechnology Co Ltd

#### **License Types:**

#### **Single User License (PDF)**

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.

- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

## Site License (PDF)\*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

## Global License (PDF)\*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

\*If Applicable.





Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

## NAVIGATE

About Us

Reports by Region

FAQ

Privacy Policy

TERMS & CONDITIONS

CONTACT

## RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

---

Source URL: <https://www.drugpipeline.net/global-markets-direct/typhoid-fever-pipeline-review-h1-2019>

Links

[1] <https://www.drugpipeline.net/region/global>